Evaluating immune responses to vaccines for yellow fever and Japanese encephalitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the immune response in healthy adults following vaccination with different combinations of yellow fever and Japanese encephalitis vaccines. Participants will be randomized into two groups receiving either the JE-YF17D vaccine followed by the YF17D vaccine or vice versa, with a third group receiving an inactivated JE vaccine. The primary objective is to compare levels of viremia after a challenge with a structurally heterologous virus. The study will involve thorough screening and informed consent processes to ensure participant safety and understanding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Healthy adults, 21-45 years of age at time of screening
2. Willing to comply to study procedures and adhere to study schedule visits.
3. Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. The laboratory values must be within the normal range of the assessing site or show abnormalities that are deemed not clinically significant as judged by the investigator. A stable health status is defined as the absence of a health event satisfying the definition of a serious adverse event.
4. Accessible vein for blood collection.
5. Ability to provide informed consent.
6. Female subjects of non-child bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Post-menopausal subjects must have had at least 12 months of natural (spontaneous) amenorrhea
7. Female subjects of child bearing potential with negative urine pregnancy tests on the day of screening and vaccination.
8. Both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills) or practice abstinence for 10 days after vaccination.

Exclusion Criteria:

1. History of presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, haematological, endocrine or immunosuppressive disorders that would be a risk factor when administered the investigational product (IP)
2. Previous receipt of Imojev, Stamaril or Ixiaro vaccines, or any other yellow fever or Japanese encephalitis vaccines
3. Previous history of Yellow fever virus or Japanese encephalitis infection
4. Known allergy to Imojev, Stamaril or Ixiaro vaccines or their components
5. History of severe food/drug/vaccine allergies e.g. angioedema, anaphylaxis
6. Known allergy to egg or egg products
7. History of thymus gland disease
8. Diagnosed with cancer or on treatment for cancer (with the exception of localized basal cell carcinoma) within 3 years prior to screening
9. Evidence of clinically significant anemia (Hb \<10 g/dl)
10. Blood donation exceeding \>450mls in the past 3 months
11. Presence of acute infection in the preceding 7 days or presence of a temperature ≥ 38.0°C (oral or tympanic temperature assessment), or acute symptoms greater than of "mild" severity on the scheduled date of first dose
12. Woman who is pregnant or breast feeding
13. Evidence of substance abuse, or previous substance abuse including alcohol
14. Participation in a study involving administration of an investigational compound (including investigational vaccines) within the past three months, or planned participation during the duration of this study.
15. Receipt of anti-inflammatory drugs (such as NSAIDs or systemic steroids) in the past 7 days.
16. Receipt of any licensed vaccine in the past 30 days before the first study vaccine dose.
17. Positive serum Dengue IgG by ELISA
18. Any condition that, in the opinion of the investigator, would complicate or compromise the study or wellbeing of the subject.

Where it's running

• SingHealth Investigational Medicine Unit
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Shirin Kalimuddin, MRCP (UK) — Singapore General Hospital
• Study coordinator: Jin Ying Ng
• Email: ng.jin.ying@singhealth.com.sg
• Phone: 63237572

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Community spread of multiple infectious diseases in Cambodia from a One Health perspective

  This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.

  Recruiting Institut Pasteur du Cambodge · Phnom Penh, Phnom Penh · NCT07358910

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

• International collaboration to collect information on adults hospitalized with acute infections

  Researchers will collect health information and biological samples from adults hospitalized with acute infections to see how these infections start, progress, and respond to care.

  Recruiting at 55 sites University of Minnesota · Tucson, Arizona and 55 other locations · NCT07069400

• Investigating how cold viruses affect bronchiectasis exacerbations

  This study is trying to see if cold viruses make symptoms worse for people with bronchiectasis compared to healthy individuals.

  Recruiting Imperial College London · London · NCT06931002

• Pharmacogenomics to improve voriconazole dosing for fungal infections

  This trial will test whether using a patient's CYP2C19 genotype with Bayesian dosing software helps get voriconazole levels into the therapeutic range by Day 8 for people with fungal infections, including those with blood cancers.

  Recruiting at 7 sites Phase 2 The University of Queensland · Seattle, Washington and 6 other locations · NCT06510699

• Survey to assess eligibility for infectious disease clinical trials

  This study is trying to find out if people are eligible to join clinical trials for infectious diseases like HIV and vaccines by having them fill out a survey about their health and background.

  Recruiting Brooklyn Clinical Research · Brooklyn, New York · NCT06492187

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.